NCT00722228View on ClinicalTrials.gov

Autologous and Allogeneic Whole Cell Cancer Vaccine for Metastatic Tumors

PHASE1/PHASE2RecruitingINTERVENTIONAL
Enrollment

50

Participants

Timeline

Start Date

July 31, 2008

Primary Completion Date

March 31, 2025

Study Completion Date

January 31, 2027

Conditions
Colorectal CancerOvarian CancerGastric CancerBreast CancerLung CancerKidney CancerMelanoma
Interventions
BIOLOGICAL

Autologous or Allogeneic tumor cells

Five vaccine doses, injected subcutaneously at 3-week intervals. Each dose is composed of irradiated and DNP-conjugated tumor cells.

Trial Locations (1)

91120

RECRUITING

Hadassah Medical Organization, Jerusalem

All Listed Sponsors
lead

Hadassah Medical Organization

OTHER